These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer. Nishio M; Ohyanagi F; Taguch F; Matsuda M; Sato Y; Okumura S; Nakagawa K; Horai T Lung Cancer; 2005 Apr; 48(1):115-9. PubMed ID: 15777978 [TBL] [Abstract][Full Text] [Related]
3. Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Takatani H; Soda H; Nakamura Y; Kinoshita A; Fukuda M; Nagashima S; Fukuda M; Soejima Y; Nakano H; Oka M; Kohno S; Jpn J Clin Oncol; 2007 May; 37(5):353-7. PubMed ID: 17599945 [TBL] [Abstract][Full Text] [Related]
4. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy. Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889 [TBL] [Abstract][Full Text] [Related]
5. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer]. Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872 [TBL] [Abstract][Full Text] [Related]
6. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study. Pectasides D; Mylonakis N; Farmakis D; Nikolaou M; Koumpou M; Katselis I; Gaglia A; Kostopoulou V; Karabelis A; Kosmas C Anticancer Res; 2003; 23(5b):4205-11. PubMed ID: 14666626 [TBL] [Abstract][Full Text] [Related]
7. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group. Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757 [TBL] [Abstract][Full Text] [Related]
8. Irinotecan in advanced lung cancer: focus on North American trials. Langer CJ Oncology (Williston Park); 2004 Jun; 18(7 Suppl 4):17-28. PubMed ID: 15255164 [TBL] [Abstract][Full Text] [Related]
9. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens. Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer. Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101 [TBL] [Abstract][Full Text] [Related]
11. Gemcitabine in the treatment of non-small-cell lung cancer. Burkes RL; Shepherd FA Ann Oncol; 1995; 6 Suppl 3():S57-60. PubMed ID: 8616118 [TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Rocha Lima CM; Rizvi NA; Zhang C; Herndon JE; Crawford J; Govindan R; King GW; Green MR; Ann Oncol; 2004 Mar; 15(3):410-8. PubMed ID: 14998842 [TBL] [Abstract][Full Text] [Related]
13. A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer. Agelaki S; Syrigos K; Christophylakis C; Boukovinas J; Varthalitis J; Pavlakou G; Athanasiadis A; Kouroussis C; Vardakis N; Maltezakis G; Milaki G; Georgoulias V; Oncology; 2004; 66(3):192-6. PubMed ID: 15218309 [TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report. Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. Lilenbaum R; Socinski MA; Altorki NK; Hart LL; Keresztes RS; Hariharan S; Morrison ME; Fayyad R; Bonomi P J Clin Oncol; 2006 Oct; 24(30):4825-32. PubMed ID: 17050867 [TBL] [Abstract][Full Text] [Related]
16. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study. Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714 [TBL] [Abstract][Full Text] [Related]
17. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. Ohyanagi F; Taguchi F; Horai T; Kasahara K; Takeda Y; Shibata K; Shirosaki H; Nishio M Jpn J Clin Oncol; 2006 Sep; 36(9):547-51. PubMed ID: 16870693 [TBL] [Abstract][Full Text] [Related]
19. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy. Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204 [TBL] [Abstract][Full Text] [Related]
20. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]